Enteropathy-associated T-cell lymphoma
MONDO:0019473An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is seen with increased frequency in regions with a high prevalence of celiac disease.
Also known as: EATL, EATL, type I, ETTL, enteropathy associated T-cell lymphoma, enteropathy-associated T-cell lymphoma, type I, enteropathy-type T-cell lymphoma, intestinal T-cell lymphoma, EATCL
1939 clinical trials for this condition and its sub-types, 20 tagged with Enteropathy-associated T-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Enteropathy-associated T-cell lymphoma
-
Can adding linperlisib to standard chemotherapy improve outcomes in rare T-Cell lymphoma?
Disease control OngoingResearchers are testing whether adding the experimental drug linperlisib to standard CHOP chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma. The trial enrolls about 44 participants who have not received prior treatment. Everyone receives six cycles of the …
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Experimental combo targets tough T-Cell lymphoma
Disease control PausedThis phase 1 trial is testing whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior treatment. Up to 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The stu…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New combo shows promise against tough lymphoma
Disease control OngoingThis phase 2 trial tests a new combination treatment for a rare type of lymphoma (CD30-positive peripheral T-cell lymphoma). It combines a targeted drug (brentuximab vedotin) with standard chemotherapy. The goal is to see if this approach improves the number of patients who achie…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Engineered donor cells take aim at tough blood cancers in early trial
Disease control PausedThis early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Vitamin d boost may extend life in lymphoma patients, trial hopes
Disease control OngoingThis study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising combo tackles rare blood cancer in chinese patients
Disease control OngoingThis study tests a combination of brentuximab vedotin plus standard chemotherapy (CHP) in 52 Chinese adults with a rare type of lymphoma called CD30+ peripheral T-cell lymphoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants rec…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo shows promise for rare blood cancer
Disease control OngoingThis early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Lymphoma drug combo trial pulled before it started
Disease control CancelledThis study was designed to test whether adding the drug tazemetostat to standard CHOP chemotherapy could improve outcomes for people with certain types of T-cell lymphoma. The trial was withdrawn before enrolling any participants, so no results are available. It would have includ…
Phase 2 • Sponsor: Eric Jacobsen, MD • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC